VBI Vaccines to Present at Upcoming Investor Conferences

On June 17, 2020 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that members of the management team will participate in the following upcoming virtual investor conferences (Press release, VBI Vaccines, JUN 17, 2020, View Source [SID1234561181]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Raymond James’ Human Health Innovation Conference

– Presentation: Thursday, June 18, 2020 from 2:20-2:50 PM ET
– Webcast: View Source

BMO 2020 Prescription for Success Healthcare Conference

– Presentation: Tuesday, June 23, 2020 from 8:00-8:25 AM ET
– Webcast: View Source

Live webcasts of the presentations will also be available on the Investors page of VBI’s website at: View Source A replay of each webcast will be archived on the company’s website for 90 days following the presentation.

Centene Recommends Stockholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation

On June 17, 2020 Centene Corporation (NYSE: CNC) reported that it has been notified of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation ("TRC Capital") to purchase up to 2,000,000 shares of Centene’s common stock at an offer price of $59.00 net per share in cash, which is an approximate 4.75% discount to the $61.94 per share closing price of Centene’s common stock on the New York Stock Exchange on June 12, 2020, the last trading day before the commencement of TRC Capital’s mini-tender offer, and an approximately 7.13% discount to the $63.53 per share closing price of Centene’s common stock on June 17, 2020, the day of this release (Press release, Centene , JUN 17, 2020, https://www.prnewswire.com/news-releases/centene-recommends-stockholders-reject-mini-tender-offer-by-trc-capital-investment-corporation-301079145.html [SID1234561197]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Centene does not endorse TRC Capital’s mini-tender offer and is not associated in any way with TRC Capital, its mini-tender offer or its mini-tender offer documents.

Centene recommends that its stockholders reject the offer and not tender their shares in response to TRC Capital’s below-market offer. This mini-tender offer is at a price below the market price for Centene’s common stock (as of today’s close) and is subject to a number of conditions, including, among others, that there has not been a decrease in the market price of shares of Centene common stock and TRC Capital’s ability to obtain debt financing sufficient, together with cash on hand, to consummate the offer.

TRC Capital has made similar mini-tender offers for the shares of other companies. TRC Capital’s mini-tender offer seeks less than 5% of Centene’s outstanding common stock, thereby avoiding many disclosure requirements and procedural protections of the Securities and Exchange Commission ("SEC"). The SEC has cautioned investors about mini-tender offers in an investor alert, advising that some bidders make mini-tender offers at below-market prices "hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price." The SEC’s cautionary alert for investors regarding mini-tender offers is on its website at: View Source

Stockholders should obtain current market quotations for their shares of Centene common stock, consult with their broker or financial advisor, and exercise caution with respect to TRC Capital’s mini-tender offer. Stockholders who have already tendered shares are advised that they may withdraw their shares by providing the written notice described in the TRC Capital mini-tender offer documents prior to the expiration of the offer, currently scheduled for 12:01 a.m., New York City time, on Wednesday, July 15, 2020.

Centene encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure at View Source

Centene requests that a copy of this press release be included with all distributions of materials relating to TRC Capital’s mini-tender offer for Centene common stock.

GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares

On June 17, 2020 GlaxoSmithKline plc ("GSK"), acting through its subsidiary GSK Finance (No.3) plc ("the issuer") reported its intention to offer senior notes due 2023 ("the notes") exchangeable into ordinary shares of Theravance Biopharma, Inc. ("Theravance Biopharma") currently held by GSK and its affiliates (Press release, GlaxoSmithKline, JUN 17, 2020, View Source [SID1234561166]). The notes will be guaranteed by GSK and will be exchangeable at the option of noteholders during specified periods. The notes will not bear a coupon.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The notes will be exchangeable into substantially all of the 9,644,807 ordinary shares of Theravance Biopharma currently held by GSK and its affiliates. Upon exchange of the notes, the issuer expects to deliver ordinary shares of Theravance Biopharma but may, at its option under certain circumstances, deliver cash or a combination of Theravance Biopharma shares and cash. The exchange premium will be set at pricing. In connection with the offering, Theravance Biopharma will agree to file a shelf registration statement with the U.S. Securities and Exchange Commission (the "SEC") to register resales of its ordinary shares deliverable upon exchange of the notes.

GSK expects to use the net proceeds of the offering for general corporate purposes. Theravance Biopharma will not receive any proceeds from the offering.

The offering of the notes will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The notes will be offered by means of an offering memorandum solely to persons reasonably believed to be "qualified institutional buyers" (as that term is defined in Rule 144A under the Securities Act) that are also "qualified purchasers" (within the meaning of Section 2(a)(51) of the U.S. Investment Company Act of 1940, as amended). This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes nor shall there be any sale of notes in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom (the "UK") or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The notes are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such notes will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

PROHIBITION OF SALES TO EEA AND UK RETAIL INVESTORS

The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA") or in the UK. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); or (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended, the "Insurance Distribution Directive"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the notes or otherwise making them available to retail investors in the EEA or in the UK has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the EEA or in the UK may be unlawful under the PRIIPs Regulation.

Agenus to Present at the Raymond James Virtual Human Health Innovation Conference

On June 17, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, reported that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus, will present an update on Agenus’ progress and host one-on-one meetings with investors at the Raymond James Virtual Human Health Innovation Conference on June 18, 2020 (Press release, Agenus, JUN 17, 2020, View Source [SID1234561182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, June 18, 2020

Time: 4:20 pm – 4:450 p.m. ET / Virtual Track 1

Webcast: The presentation will be webcast and can be accessed through the following link: View Source

RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO

On June 17, 2020 RemeGen, Co., Ltd. reported positive results from its Phase II study of RC48 (disitamab vedotin) for the treatment of HER2-expressing advanced or metastatic gastric cancer in heavily treated patients at the ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program organized by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), which was held on May 29-31, 2020 (Press release, RemeGen, JUN 17, 2020, View Source [SID1234561198]). RC48 (disitamab vedotin) is a novel humanized anti-HER2 antibody drug conjugate (ADC) developed to treat several cancer diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For the third year in a row, we are pleased to showcase clinical progress of RC48 in a broad range of solid tumor treatments at ASCO (Free ASCO Whitepaper)," said Jianmin Fang, Ph.D., founder and CEO of RemeGen Co., Ltd., "We are encouraged to see positive data from the latest research, and we believe that RC48 has the potential to redefine treatment for patients with HER2-expressing advanced or metastatic gastric cancer."

The single-arm Phase II multicenter clinical study conducted in China was designed to evaluate the efficacy and safety of RC48. The study enrolled 127 patients (IHC2+ including FISH+ and FISH-, and IHC3+) with advanced or metastatic gastric cancer including gastric or gastroesophageal junction adenocarcinoma. The key endpoint of the study was the objective response rate (ORR) of the main efficacy index evaluated by the independent efficacy evaluation committee (IRC). The confirmed ORR was 23.6%, with a median progression free survival period (mPFS) of 4.1 months. The median overall survival time (mOS) was 7.5 months.

All patients evaluated in the study had received 2 or more lines of chemotherapy treatments with a subgroup of patients having received an additional line of systemic therapy treatment such as Herceptin. The study also included patients with low expressing HER2 (IHC2+ / FISH-) tumor, potentially widening the population of patients who may benefit from this therapy. The results of the study demonstrate RC48’s potential in addressing the urgent unmet medical need for this heavily treated patient population.

More information around these findings are found in the virtual scientific program of the ASCO (Free ASCO Whitepaper) Annual Meeting (Abstract #4560).

About RC48
RC48 was developed to treat HER2 expressing solid tumors. It has a novel antibody with a higher affinity to HER2 compared to standard of care, and superior anti-tumor activity compared to other treatments in animal models. RC48 was the first ADC drug approved for human clinical trials in China and favorable safety profile has been observed in clinical trials. It is currently being studied in multiple late-stage clinical trials across solid tumor types.